




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

BEST AVAILABLE COPY

| | | |
|---|---|--|
| (51) International Patent Classification ⁶ : A61B 6/00 | A1 | (11) International Publication Number: WO 96/10363 (43) International Publication Date: 11 April 1996 (11.04.96) |
| (21) International Application Number: PCT/US95/12456 (22) International Filing Date: 29 September 1995 (29.09.95) (30) Priority Data: 08/316,132 30 September 1994 (30.09.94) US (71) Applicant: LOCKHEED MARTIN ENERGY SYSTEMS, INC. [US/US]; P.O. Box 2009, Oak Ridge, TN 37831-8243 (US). (72) Inventors: VO-DINH, Tuan; 12318 River Oaks Point, Knoxville, TN 37922 (US). PANAJEHPOUR, Masoud; 1222 Reston Court, Knoxville, TN 37923 (US). OVERHOLT, Bergein, F.; 5800 Lyons View Pike, Knoxville, TN 37950 (US). (74) Agent: SMIRMAN, Preston, H.; Lockheed Martin Energy Systems, Inc., P.O. Box 2009, Oak Ridge, TN 37831-8243 (US). | (81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> | |

(54) Title: LASER-INDUCED DIFFERENTIAL NORMALIZED FLUORESCENCE METHOD FOR CANCER DIAGNOSIS



(57) Abstract

This invention is an apparatus and method for diagnosing cancer in vivo. A laser (12) and tunable dye system (14) generate an output beam which is transported by an optical fiber bundle (18) to a tissue to be examined. Laser induced fluorescence emitted by the tissue is delivered through the bundle (18) to a sensor, which may include a spectrograph (24) and a multi-channel detector (26) for producing a spectrum. The spectrum is analyzed by a computer (28) that diagnoses cancerous tissue using differential normalized fluorescence, wherein the intensity at each wavelength is divided by the integrated area under the spectrum and compared with a normalized spectrum from a normal tissue sample.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | US | United States of America |
| FI | Finland | MN | Mongolia | UZ | Uzbekistan |
| FR | France | | | VN | Viet Nam |
| GA | Gabon | | | | |

LASER-INDUCED DIFFERENTIAL NORMALIZED
FLUORESCENCE METHOD FOR CANCER DIAGNOSIS

This invention was made with Government support under contract DE-AC05-84OR21400 awarded by the U.S. Department of Energy to Martin Marietta Energy Systems, Inc. and the Government
5 has certain rights in this invention.

FIELD OF THE INVENTION

The present invention relates generally to the field of medical diagnostics and, more specifically, to an improved in vivo method for
10 making a cancer diagnosis using differential normalized fluorescence (DNF). A sample is irradiated with a laser light source and the laser-induced fluorescence (LIF) of normal and malignant tissues are normalized by dividing the
15 intensity at each wavelength by the integrated area under the spectrum. Differences in the resulting DNF curves are then used as the basis for cancer diagnosis.

BACKGROUND OF THE INVENTION

20 In vivo and rapid procedures for tissue diagnosis are important for efficient cancer prevention and therapy. As an example of one type of detection, endoscopy is used to detect abnormal tissues in the human esophagus. Once

an abnormality is found, biopsies are taken for determination of histopathology.

For diagnosis, a biopsy sample usually represents a very small area. The laboratory results are generally not available for several days. Thus, the known endoscopic techniques do not provide real-time in vivo classification of the tissue type.

Recently there has been interest in using laser-induced fluorescence (LIF) in the development of diagnostic and therapeutic tools. A number of investigators have used LIF as a method to discriminate tumors from normal tissues. For example, The LIF technique has been used to distinguish adenomatous polyps from normal colon tissue and hyperplastic polyps in vitro. See C.R. Kapadia et al., "Laser-Induced Fluorescence Spectroscopy of Human Colonic Mucosa - Detection of Adenomatous Transformation," Gastroenterology, 99: 150-157 (1990).

Still others have investigated the LIF technique to distinguish adenomatous tissue from normal colon tissue in vivo. See R.M. Cothren et al., "Gastrointestinal Tissue Diagnosis By Laser-Induced Fluorescence Spectroscopy at Endoscopy," Gastrointestinal Endoscopy, 36: 105-111, (1990). Fluorescence techniques have also been used to characterize normal and malignant breast tissues, lung tissues, and to quantify photodynamic therapy drugs in rat tissues. A fiber optic LIF antibody-based biosensor has been used to detect DNA modification by carcinogenic chemicals in human placenta samples.

Other investigators have used LIF and multivariate linear regression analysis to distinguish neoplastic tissue from non-neoplastic tissue. See K.T. Schomacker et al.,
5 Ultraviolet Laser-Induced Fluorescence of Colonic Tissue: Basic Biology and Diagnostic Potential," Lasers In Surgery and Medicine, 12: 63-68 (1992).

The Schomacker et al. data suggest that the
10 LIF measurements detected changes in polyp morphology rather than changes in fluorosphores specific to polyps, and it was this change in morphology that leads indirectly to discrimination of polyps. Schomacker et al.
15 concluded that the feasibility of discriminating groups of normal from dysplastic cells by LIF is as yet undemonstrated.

U.S. Patent No. 4,930,516 to Alfano et al. describes a method for detecting cancerous
20 tissue using laser-induced fluorescence. The wavelengths at which maximum intensities are attained for sample tissue are determined and compared to peak wavelengths derived from known non-cancerous tissue.

25 U.S. Patent No. 5,131,398 to Alfano et al. describes a method of distinguishing cancerous tissue from benign tumor tissue uses a light source which produces a 300-nm monochromatic light beam which is directed into the sample
30 through an endoscope. Emission radiation produced by fluorescence is measured at 340 and 440 nm, and a ratio of the two intensities is then calculated and used as a basis for determining if the tissue is cancerous.

A further endoscopic technique is described in U.S. Patent No. 5,261,410 to Alfano et al. uses an infrared monochromatic light source, and then measures the Raman shift in emission
5 radiation to ascertain the condition of a tissue sample.

The foregoing references and studies detailed therein indicate that there remains a strong need to develop improved procedures for
10 effective cancer diagnosis.

SUMMARY OF THE INVENTION

An object of the present invention is to provide a method of performing in vivo cancer diagnosis without requiring biopsy.

15 Another object of the present invention is to provide a method of performing an in vivo medical diagnosis in which the results can be obtained quickly and reliably.

Yet another object of the present invention
20 is to provide a method and apparatus of performing an in vivo medical diagnosis using laser-induced fluorescence wherein the spectral changes are less dependent on spectral intensity and thus more reliably indicative of a tissue
25 condition.

Still another object of the present invention is to provide a method and apparatus wherein small changes in weak signals from malignant tissues are amplified by the
30 differential normalization procedure for improved analysis.

These and other objects of the invention are met by providing a method of performing a medical diagnosis which includes the steps of

irradiating a tissue sample with a monochromatic
excitation light having a predetermined
wavelength, producing a laser-induced
fluorescence spectrum from emission radiation
5 generated by interaction of the excitation light
with the tissue sample, dividing the intensity
at each wavelength of the spectrum by the
integrated area under the spectrum to produce a
normalized spectrum, and correlating the
10 normalized spectrum to a specific condition of
the tissue sample.

An apparatus for performing the diagnostic
method includes a laser source producing a beam
at 410 nm for cancer of the esophagus.

15 Other objects, advantages and salient
features of the invention will become apparent
from the following detailed description, which
taken in conjunction with the annexed drawings,
discloses preferred embodiments of the
20 invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic view of an
apparatus for conducting a differential
normalized fluorescence diagnostic method of the
25 present invention;

Figures 2(a) and 2(b) are graphs showing
fluorescence emission of a normal tissue using
non-normalized and normalized data,
respectively;

30 Figure 3 is a graph showing (a) DNF of a
normal esophageal mucosa and (b) DNF of an
esophageal adenocarcinoma, with curve (b)
showing a negative peak at 475-480 nm which is

characteristic of malignant tissue in the esophagus;

Figure 4 is a graph showing a differential normalized index at 480 nm, with results of histopathology assays marked on the graph for normal tissues and malignant tissues; and

Figure 5 is a graph showing average differential normalized fluorescence values at 480 nm for various tissues.

10 DETAILED DESCRIPTION OF THE INVENTION

Referring to Figure 1, an instrument 10 for conducting cancer diagnosis in vivo can be set up in an operating room of a hospital or other suitable examination room. A source 12 of monochromatic excitation light produces a pulsed beam which is tuned to a specific wavelength by a dye head (DYE) 14. Preferably, for detecting and differentiating normal and malignant tumors of the esophagus, the source 12 is a pulsed nitrogen-pumped dye laser (model LN300C Laser Photonics, Inc., Orlando, Florida USA) tuned to 410 nm.

The pulsed output beam passes through a focusing lens 16 and into a bifurcated optical fiber bundle 18. The bundle 18 includes, for example, seven 200- μ m diameter fibers for excitation and twelve 200- μ m diameter fibers for emission. The bundle is designed so that it can be inserted into the biopsy channel of an endoscope 20. The distal end of the bundle is juxtaposed to the tissue in vivo for analysis, and preferably touching the tissue (although not necessarily).

Emission radiation in the form of laser-induced fluorescence is delivered through the bundle 18 to a focusing lens 22, which is optional, and then to a sensor means. The sensor means may include a spectrograph (SPEC.) 24 and multichannel detector (DET.) 26. In a preferred embodiment, the detector 26 is an intensified photodiode array (model OMA III, EG&G Princeton Applied Research, Princeton, New Jersey USA) equipped with a spectrograph (model 1235 EG&G) for spectral dispersion. Alternatively, a polychromator or other light detectors may be used.

The output signal from the light detector is delivered to a computer 28 which is supplied with commercially available data acquisition software.

In an alternate embodiment the detector can be a gated multichannel detector operated in a time-resolved mode with a delay time optimized to the lifetime of fluorescent components of interest in tissues. Selection of appropriate gate and delay times can further enhance spectral features.

Yet in another alternate embodiment, the excitation laser intensity can be modulated and the detector synchronized in a phase-resolved mode to improve detection, sensitivity, and selectivity.

Procedures for Clinical Measurements

All measurements were conducted during routine gastrointestinal endoscopy examinations of patients. The fiber optic probe was inserted into the biopsy channel of the endoscope. The

distal end of the fluorescence probe is positioned to lightly touch the surface of the tissue being monitored. Each LIF reading corresponded to fluorescence measurements for ten excitation pulses. The system is programmed to take the fluorescence for each laser pulse. Background reading is subtracted from the accumulated data and the resulting spectra are stored in a special data file. A minimum of three readings are recorded for each tissue site. A small light source located close to the endoscopic monitor sends flashes for every laser pulse delivered to the tissue. These flashes allow the endoscopist to visually determine the exact site of analysis and to ensure proper contact of the probe to the tissue during fluorescence measurements. The reading is completed in approximately 0.6 seconds for each tissue site.

In general, the LIF spectra of normal and malignant tissues exhibit certain differences at several wavelengths. However, it is difficult to observe subtle but consistent differences in the raw data because these differences are often masked by large variations in intensity.

An example of fluorescence emission of a normal tissue and a malignant tissue is illustrated in Figure 2(a). The laser excitation wavelength was selected to be 410 nm. To develop an effective technique capable of differentiating normal and malignant tissues, it is essential to investigate and select the optimal experimental conditions and parameters affecting the results of LIF measurements. The first such parameter is the laser excitation

wavelength. With a nitrogen laser, the lowest excitation wavelength (highest energy) available is 337 nm. Longer wavelengths could be selected for excitation by using the tunable dye system
5 14 of Figure 1.

In general, the use of shorter wavelengths would excite more components, whereas as the use of longer wavelengths would excite less components in tissues. The choice of the laser
10 excitation wavelength is important since, with a fixed excitation laser, it is not possible to excite all tissue components in a single measurement. One approach is to excite as many tissue components as possible at the wavelengths
15 where they exhibit the strongest absorption. This approach, however, does not necessarily produce the best results since certain important but subtle spectral changes could be masked by strong but non-specific absorption bands. After
20 performing a number of experiments, the 410- nm laser wavelength was selected for certain cancers. This wavelength produces fluorescence spectra having certain specific spectral features that are useful to the development of
25 the present diagnostic methodology.

The data in Figure 2(a) show that the fluorescence intensity of the malignant tissue (right curve) is much weaker than that of the normal tissue (left curve). However, this
30 general observation based on the intensity is often difficult to be used in practice because the intensity of the recorded fluorescence signals are not always a consistent parameter as it depends on many factors including blood flow,
35 hemoglobin absorption, tissue surface

morphology, distance between the tissue surface and the probe, etc. For comparison purposes, the two spectra in Figure 2(a) are plotted on the same intensity scale. It is noteworthy that
 5 the detection of small spectral structures in the weak fluorescence signal from the malignant tumor (Figure 2(a), right curve) are generally difficult.

Whereas the intensity of the fluorescence
 10 is always not a consistent parameter, the present invention takes into account that the spectral profile of each spectrum contained specific characteristics that are more consistent. Based on this observation, the
 15 present invention uses the differential normalized fluorescence (DNF) to enhance small but consistent spectral differences between the normal and malignant tissues.

In order to amplify and compare the
 20 spectral features in fluorescence spectra of normal and malignant tissues, the present invention uses a normalization process that divides the intensity at each wavelength by the integrated area under the total spectrum. The
 25 normalized fluorescence intensity I_n at wavelength i for sample K , i.e., $I_n(K)_i$, is given by:

$$I_n(K)_i = I(K)_i / \sum_i I(K)_i$$

where $I(K)_i$ is the fluorescence at wavelength i
 30 for sample K , and
 \sum_i corresponds to the summation of fluorescence intensities at all wavelengths i over the spectral range investigated.

Figure 2(b) illustrates the effect of this procedure for the same normal esophageal tissue (left curve) and the same malignant esophageal tissue (right curve). This procedure is
5 designed to produce two important effects on the fluorescence data. First, it produces a "normalization" effect. Since each spectrum is normalized with respect to the integrated
10 intensity of the entire spectrum, the resulting spectrum becomes less dependent on the intensity factor.

It is noteworthy that the normalized intensity I_n has a dimensionless value since it is the ratio of an intensity (dimension in
15 photons) divided by a sum of intensities $\sum_i I(K)_i$, (which also has a dimension in photons).

Another important effect of this normalization procedure is the enhancement of small spectral features in weak fluorescence
20 signals. This unique effect of the DNF method is essential for the diagnosis of malignant tissues, which generally exhibit weak fluorescence whose small features are difficult to detect. As the result of this normalization
25 procedure, the differences in spectral features between the normalized fluorescence spectra of normal and malignant tissues becomes more easily detected (see Figure 2(b) section: compare left and right curve).

30 As shown in Figure 2(b), the two noticeable features were the spectral features at 460-490 nm and 640-670 nm. A depleted area at approximately 475-480 nm can be observed in the spectra of malignant tissues. This spectral
35 depletion reflected deficiency of certain

components (or absorption by some compound) in malignant tissues, which normally fluoresce at 460-490 nm. This spectral deficiency (i.e., "negative peak") provides an important criterion for malignant tissue diagnosis. To our knowledge, this important spectral feature has not been reported in any previous studies.

Another important feature in the normalized fluorescence spectra is that several bands between 640 and 670 nm in the fluorescence spectra of malignant tumors are relatively more intense than those of normal tissues. In addition there are also minor spectral features noticeable in the normalized curve of malignant tissues (Figure 2(b)) at 590 and 625 nm.

Using the normalized spectra, we have developed a DNF technique designed at exploiting these spectral differences between normal and malignant tissues. Noticing that the normalized fluorescence spectra of all normal tissues have similar spectral profile, we established a "baseline curve" for normal tissues. This baseline curve was determined as the mean average of normalized fluorescence spectra from a reference set of normal tissue samples. The intensity of this baseline curve, I_B , at wavelength i is given by:

$$I_{Bi} = \left(\frac{1}{n_B} \right) \times \sum_B I(B)_i \quad (2)$$

where \sum_B corresponds to a normal tissue B used in the baseline set.

It is noteworthy that this procedure requires the identification of a set of normal tissues (and patients) a priori in order to establish the baseline curve. The data
 5 necessary for the baseline curve can be initially based on histopathology assay data. Once the baseline curve is established, it can be used for all future measurements, and the fluorescence characteristics of each tissue can
 10 be compared to this baseline curve.

After the establishment of the baseline fluorescence curve, the DNF curve for a specific tissue sample of interest was calculated as the difference between its normalized fluorescence
 15 spectrum I_n and the baseline curve I_B . This procedure involved subtracting the intensity of the baseline curve from the normalized intensity curve of the sample of interest. The DNF Intensity of particular tissue sample K at
 20 wavelength i is given by:

$$I_{DNF}(K)_i = I_n(K)_i - I_B$$

(3)

The DNF spectrum, i.e., the plot of intensity $I_{DNF}(k)_i$ versus wavelength i , is illustrated in Figure 3. This figure shows the
 25 DNF curves corresponding to a normal tissue and a malignant tumor in sections A and B, respectively, after subtraction of the baseline curve I_{Bi} as described in Equation 3. As expected, the DNF curve that corresponds to a
 30 normal tissue is a line close to the horizontal baseline, since there is little difference between the normalized fluorescence spectrum of a given normal tissue and the mean average of a

reference set of normal tissues, I_{Bi} . On the other hand, one expects to observe some differences between the normalized fluorescence of a malignant tumor and I_{Bi} . The results of the DNF procedure confirmed this important feature and clearly showed a negative peak at 475-480 nm for malignant tissues as illustrated in Figure 3.

The I_{DNF} values at 480 nm are shown in Figure 4 for a set of samples from a data base of 300 measurements with over 80 patients. Biopsies of normal and malignant tissue samples from patients investigated by laser-induced fluorescence were also analyzed histopathologically with results shown in Figure 4. The normal tissues labeled by a dot (.), and malignant tissues labeled by a cross (+). The results show that all 35 malignant tumors have a negative DNF-1 index with a value less than -7.5×10^{-3} , which corresponds to the negative peak in malignant tissue fluorescence discussed previously in Figure 2. On the other hand, the values of the DNF-1 index of all 79 normal tissues, except for one sample, are distributed around zero (between -5×10^{-4} and 5×10^{-4}) as expected since they come from the difference between the normalized fluorescence curve of a normal tissue and the baseline curve of a set of normal tissues.

Classification of Carcinoma and Normal Tissues

In a study using the methodology of the present invention, data related to the first 30 patients were made available to the investigators in order to compare with

fluorescence data, to calculate the baseline curve, and to develop the DNF model. After this initial phase, all the measurements were "blind tests" and the DNF model was used to "predict" the diagnosis of tissues for all other patients. For this blind test phase, histopathology test results were unknown a priori by the investigators.

As shown in Figure 4, classification of malignant tissues using the DNF-1 indices is in excellent agreement with histopathological results for the set of patients monitored in this study. In the data set shown in Figure 4, all 35 malignant tissues detected by the DNF method are in excellent agreement with biopsy results. From 77 normal tissues classified as normal by the DNF method, only one was found to be malignant by histopathological assays. Although the exact causes of this misclassification is not completely understood, a possibility might be due to the fact that the area monitored by the optical technique was not exactly the same location where the biopsy was made. Other DNF readings in this patent classified correctly.

Two interesting cases are shown in Figure 4 by two stars (*). These two samples, which are related to the same patient, were first diagnosed to be normal tissues by the conventional biopsy procedure. However, the laser-based DNF method classified these samples to be malignant. The decision was made to rediagnose this patient using an independent procedure (viz., CAT scan method). The computer assisted tomography (CAT) scan measurements

revealed that this patient had lung cancer that had spread into areas underlining the esophagus mucosa. This example underscores the effectiveness of the optical DNF technique to
5 diagnose malignant tissues that could have been misdiagnosed by the conventional biopsy method.

It is noteworthy that this study uses the normal (i.e., 0th order) normalized spectra (Figures 2b) and 0th order DNF curves (Figure
10 3). In certain cases, small spectral features in the curves can be further enhanced by using first-derivative, second-derivative or n^{th} derivative curves.

Analysis of Barrett's Esophagus

15 In addition to normal and malignant tissues, there is a type of dysplasia, called Barrett's esophagus, which is difficult to detect by conventional endoscopy. Figure 5 shows the average values of the DNF index at 480
20 nm corresponding to various types of tissues: normal esophagus, normal Barrett's mucosa (BAR.-N), low-to-moderate dysplasia (BAR.LM), moderate-to-severe dysplasia (BAR.MS), severe dysplasia (BAR.S), and carcinoma.

25 In order to discuss the results in Figure 5, it is useful to understand the nature of Barrett's tissues. Barrett's esophagus, a progressive columnar metaplasia of the lower esophagus, is a premalignant condition with an
30 increased risk of adenocarcinoma. In this work the diagnostic procedure for Barrett's esophagus is different from that of carcinoma normal tissues. Carcinoma tissues are often clear-cut cases that can be visually seen by the physician

through his or her endoscope. Therefore, it was possible to perform an optical LIF measurement on a specific area and later perform a biopsy on the same location. With this procedure, it is possible to have a precise (one-to-one) comparison between the two methods for one type of tissue. Barrett's tissues do not often correspond to visually clear-cut cases. In Barrett's esophagus, the original squamous epithelial cell lining of the esophagus is replaced by a metaplastic columnar-type epithelium, often given rise to a mixture of tissue islands of columnar epithelium with diffuse boundaries.

In testing the present techniques, rapid performance of LIF measurements occurred first, and then biopsies were taken in the same areas. Approximately 5-7 LIF measurements in different locations can be taken in the same time required for one regular biopsy. Although great care was taken to perform the biopsies in the areas previously measured by LIF, it is often difficult to find the exact locations of the Barrett's tissues that had been previously analyzed by LIF. Therefore, for Barrett's esophagus tissues, it is not possible to have a precise and exact comparison between the optical DNF results and the biopsy data.

The data related to Barrett's esophagus is presented with the average DNF values of the Barrett's tissues grouped in the different classifications used by the pathologist, i.e., BAR.N, BAR.M-L, BAR.M-S, BAR.S.

The results in Figure 5 indicate that the DNF index at 480 nm show an interesting general

trend: the more severe the Barrett's dysplasia, the more negative the average DNF index value. For example, tissues designated as Barrett's normal and Barrett's low-to-medium have DNF values close to zero (i.e., similar to normal tissues). Tissues designated by the pathologist as Barrett's medium-to severe have an average DNF value approximately 7.5×10^{-4} , whereas Barrett's severe tissues have DNF values at approximately 15×10^{-4} . Carcinoma tissues have an average DNF value at approximately 17×10^{-4} . It is noteworthy that these results provide a general trend which could be used to improve the diagnosis of dysplasia in Barrett's esophagus. Improved procedures to diagnose Barrett's dysplasia in esophagus are currently under investigation in our laboratories.

The present invention provides a unique technique that can provide effective indices to diagnose malignant tumors in the esophagus. The DNF indices, which are derived from in-vivo laser-induced fluorescence measurements, have provided excellent results in the diagnosis of malignant tumors of the esophagus. From the total of 114 samples studied, there is only one case where the DNF result differs from the biopsy data. There are two samples in which the DNF method reveals malignance in tissues that were missed by the biopsy method.

The DNF procedure also provides a general trend which corresponds to severity of dysplasia for Barrett's esophagus. Thus, using the present DNF method, one can provide a rapid in vivo technique for cancer diagnosis which does

not require biopsy, thus decreasing the time and cost of cancer prevention and treatment.

5 While advantageous embodiments have been chosen to illustrate the invention, it will be understood by those skilled in the art that various changes and modifications can be made therein without departing from the scope of the invention as defined in the appended claims.

WHAT IS CLAIMED IS:

1. A method of performing a medical diagnosis comprising the steps of:

exposing a tissue sample to a monochromatic excitation light having a predetermined

5 wavelength;

producing a fluorescence spectrum from emission radiation generated by interaction of the excitation light with the tissue sample;

10 subtracting the normalized spectrum from the average value of a reference set of harmonized spectra of normal tissues, to produce a differential normalized fluorescence (DNF) curve; and

15 correlating the differential normalized spectrum to a specific condition of the tissue sample.

2. A method according to claim 1, wherein the exposing step comprises exposing the tissue sample to a monochromatic excitation light having a wavelength of about 410 nm.

3. A method according to claim 1, wherein the correlating step comprises identifying a set of normal tissues a priori in order to establish a baseline, dividing the intensity at each
5 wavelength of the spectrum by the integrated area under the spectrum to produce a normalized spectrum, and comparing the normalized spectrum to the baseline.

4. A method according to claim 1, wherein the correlating step comprises determining a wavelength at which normal tissue fluoresces and identifying depletions in the fluorescence of normal tissue.

5. A method according to claim 1, wherein the correlating step comprises comparing the first and/or second or n^{th} derivative curves of the normalized spectra.

6. A method according to claim 3, wherein the correlating step comprises comparing the first, second, or n^{th} derivative curves of the differential normalized fluorescence spectra.

7. An apparatus for performing a medical diagnosis comprising:

means for radiating a tissue sample to a monochromatic excitation light having a
5 predetermined wavelength;

means for producing a laser-induced fluorescence spectrum from emission radiation generated by interaction of the excitation light with the tissue sample;

10 means for dividing the intensity at each wavelength of the spectrum by the integrated area under the spectrum to produce a normalized spectrum; and

15 means for correlating the normalized spectrum to a specific condition of the tissue sample.

8. An apparatus according to claim 7, wherein the radiating means comprises a laser having a wavelength of about 410 nm.

9. An apparatus according to claim 8, wherein the radiating means further comprises an endoscope and a fiber optic bundle for directing excitation light into the endoscope and
5 detecting emission radiation from the tissue through another fiber optic bundle.

10. An apparatus according to claim 7, wherein the radiating means comprises a pulsed laser and the correlating means is a gated photodetector used in a time-resolved mode.


11. An apparatus according to claim 7, wherein the radiating means comprises a pulsed laser having a wavelength of about 410-nm, and the correlating means is a gated photodetector used
5 in a time-resolved mode.

12. An apparatus according to claim 7, wherein the radiating means comprises a modulated laser and the correlating means comprises a
5 synchronized photodetector operated in a phase-resolved mode.

13. An apparatus according to claim 7, wherein the radiating means comprises a laser producing an amplitude-modulated light at about 410-nm, and the correlating means comprises a
5 synchronized detector operated in a phase-resolved mode.

14. An apparatus according to claim 8, wherein the fluorescence is performed at about 480-nm.
15. An apparatus according to claim 8, wherein the fluorescence is performed at around 660-nm.

FIG. 1






FIG. 2

FIG. 3




FIG. 4

DIFFERENTIAL NORMALIZED

INDEX

INTENSITY @ 480 nm





FIG. 5

AVERAGE DIFFERENTIAL
NORMALIZED INDEX

INTENSITY @ 480 nm



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/12456

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61B 6/00

US CL :128/665

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 128/633, 634, 665; 606/15, 16

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

NONE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---------------|---|-----------------------|
| X | US, A, 4,479,499 (ALFANO) 30 October 1984, see column 5 lines 4-48; and column 7 lines 1-16. | 1, 2, 4 |
| A | US, A, 5,003,977 (SUZUKI ET AL.) 02 April 1991. | 1, 2, 4 |
| Y | US, A, 5,115,137 (ANDERSSON-ENGELS ET AL.) 19 May 1992, see column 3 lines 19-44. | 2 |
| X --- Y | US, A, 5,131,398 (ALFANO ET AL.) 21 July 1992, see column 3 lines 5-23; and column 5 lines 16 and 17. | 1, 4 ----- 2 |

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

| | |
|---|--|
| * Special categories of cited documents: | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| *A* document defining the general state of the art which is not considered to be part of particular relevance | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| *E* earlier document published on or after the international filing date | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *G* document member of the same patent family |
| *O* document referring to an oral disclosure, use, exhibition or other means | |
| *P* document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

13 DECEMBER 1995

Date of mailing of the international search report

30 JAN 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ERIC F. WINAKUR

Telephone No. (703) 308-3940

(19) 日本国特許庁 (J P)

(12) 公表特許公報 (A)

(11) 特許出願公表番号

特表平9-506027

(43) 公表日 平成9年(1997)6月17日

| | | | | |
|---------------------------|-------|---------|---------------|---------|
| (51) Int.Cl. ⁸ | 識別記号 | 庁内整理番号 | F I | |
| A 6 1 B 10/00 | | 8825-4C | A 6 1 B 10/00 | T |
| | | 8825-4C | | E |
| // A 6 1 B 1/00 | 3 0 0 | 0277-2J | 1/00 | 3 0 0 D |

審査請求 未請求 予備審査請求 未請求(全 21 頁)

(21) 出願番号 特願平8-512027
 (86) (22) 出願日 平成7年(1995)9月29日
 (85) 翻訳文提出日 平成8年(1996)5月30日
 (86) 国際出願番号 PCT/US95/12456
 (87) 国際公開番号 WO96/10363
 (87) 国際公開日 平成8年(1996)4月11日
 (31) 優先権主張番号 08/316, 132
 (32) 優先日 1994年9月30日
 (33) 優先権主張国 米国 (US)


(71) 出願人 ロッキード・マーチン・エナジー・システムズ・インク
 アメリカ合衆国、テネシー州 37831-8243、オーク・リッジ、ビー・オー・ボックス 2009
 (72) 発明者 ヴォーデン、チューアン
 アメリカ合衆国、テネシー州 37922、クノックスビル、リバー・オークス・ポイント 12318
 (72) 発明者 バナジェブ、マソード
 アメリカ合衆国、テネシー州 37923、クノックスビル、レストン・コート 1222
 (74) 代理人 弁理士 山崎 行造 (外1名)
 最終頁に続く

(54) 【発明の名称】 レーザ誘導微分正規化蛍光式癌診断方法及び装置

(57) 【要約】

本発明は生きたままの癌を診断する装置及び方法である。レーザ12及び調整可能な染色システム14が出力光線を生じさせ、その光線が光学繊維束18によって検査すべき組織に運ばれる。組織によって発せられるレーザ誘導蛍光が、束18を通してスペクトログラフ24を有するセンサ及びスペクトルを生成させる多重チャンネル検出器26へ伝えられる。スペクトルは、微分正規化された蛍光を用いて癌性組織を診断するコンピュータ28で分析され、そこでは各波長における強度が、スペクトル内の統合された領域によって分割され、正常な組織サンプルからの正規化されたスペクトルと比較される。

FIG. 1



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.